An open-label, single-arm, prospective study of TACE combined with apatinib for unresectable liver metastases from colorectal cancer
Latest Information Update: 06 Nov 2017
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- 06 Nov 2017 New trial record